Experimental Leishmania (L.) amazonensis Leishmaniasis: Characterization and Immunogenicity of Subcellular Fractions

REFERENCES

• Alexander J. A radio attenuated Leishmania major vaccine markedly increases the resistance of CBA mice to subsequent infection with Leishmania mexicana mexicana. Trans. Roy. Soc. Trop. Med. Hyg. 1982; 76: 646–649
   PubMedGoogle Scholar
• Andrade Z., Andrade S. G., Sadigursky M. Enhancement of chronic Trypanosoma cruzi myocarditis in dogs treated with low doses of cyclophosphamide. Am. J. Pathol. 1987; 127(3)467–473
   PubMedGoogle Scholar
• Angelopoulos E. Pellicular microtubules in the family Trypanosomatidae. J. Protozool. 1970; 17: 39–51
   PubMedGoogle Scholar
• Askenase P. H., Hayden B. J., Gershon R. K. Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses. J. Exp. Med. 1975; 141(3)697–702
   PubMedGoogle Scholar
• Bradford M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye biding. Anal. Biochem. 1976; 72: 248–254
   PubMed Web of Science ®Google Scholar
• Calabrese K. S. Immunosuppressive drugs as a tool to explore immunopathology in experimental Chagas disease. Mem. Inst. Oswaldo Cruz. 1999, Suppl. I: 273–276
   PubMedGoogle Scholar
• Champsi J., McMahon-Pratt D. Membrane glycoprotein M-2 protects against Leishmania amazonensis infection. Infect. Immun. 1988; 56: 3272–3279
   PubMed Web of Science ®Google Scholar
• de Souza W., da Cunha-e-Silva N. L. Cell fractionation of parasitic protozoa: a review. Mem. Inst. Oswaldo Cruz. 2003; 98: 151–170
   Google Scholar
• Dereure J., Thanh H. D., Lavabre-Bertrand T., Cartron G., Bastides F., Richard-Lenoble D., Dedet J. P. Visceral leishmaniasis. Persistence of parasites in lymph nodes after clinical cure. J. infect. 2003; 47: 77–81
   PubMed Web of Science ®Google Scholar
• Drummelsmith J., Brochu V., Girard I., Messier N., Ouellette M. Proteome mapping of the protozoan parasite Leishmania and application to the study of drug targets and resistance mechanisms. Mol. Cell. Proteom. 2003; 2: 146–155
   PubMed Web of Science ®Google Scholar
• Dubuy H. G., Mattern C. F., Riley F. L. Isolation and characterization of DNA from kinetoplasts of Leishmania enriettii. Science 1965; 12: 754–766
   Google Scholar
• Gazda L. S., Baxter A. G., Lafferty K. J. Regulation of autoimmune diabetes: characteristics of non-islet-antigen specific therapies. Immunol. Cell. Biol. 1996; 74: 401–407
   PubMed Web of Science ®Google Scholar
• Gonçalves Da Costa S. C., Barbosa-Santos E. G. O., Lagrange P. H. Vaccination of mice against Leishmania mexicana amazonensis with polysomal fraction associated with BCG. Ann. Immunol. (Institut Pasteur) 1988; 139: 143–156
   PubMedGoogle Scholar
• Gonçalves Da Costa S. C., Lagrange P. H. Development of cell mediated immunity to flagellar antigens and acquired resistance to infection by Trypanosoma cruzi in mice. Mem. Inst. Oswaldo Cruz 1981; 76: 367–381
   PubMedGoogle Scholar
• Handman E. Leishmaniasis: current status of vaccine development. Clin. Microbiol. Rev. 2001; 14: 229–243
   PubMed Web of Science ®Google Scholar
• Hermeto M. V., Vieira-Dias D., Genaro O., da Costa C. A., Toledo V. P., Michalick M. S., Tafuri W. L., Chaves K. M., Mayrink W. Delayed hypersensitivity skin using Leishvacin for epidemiological survey of canine cutaneous leischmaniasis in rural area of Minas Gerais state Brasil. Mem. Inst. Oswaldo Cruz 1993; 88: 635–636
   PubMedGoogle Scholar
• Hodgkinson V. H., Herman R., Semprevivo L. Leishmania donovani correlation among assays of amasaigotes viability. Exp. Parasitol 1980; 50: 397–408
   PubMed Web of Science ®Google Scholar
• Johnson P., Neal R. A., Gall D. Protective effect of killed trypanosome vaccines with incorporated adjuvants. Nature 1963; 5: 200–283
   Google Scholar
• Khalil E. A., El Hassan A. M., Zijlstra E. E., Mukhtar M. M., Ghalib H. W., Musa B., Ibrahim M. E., Kamil A. A., Elsheikh M., Babiker A., Modabber F. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan. Lancet 2000; 356: 1565–1569
   PubMed Web of Science ®Google Scholar
• Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 15:227(5259)680–685
   Google Scholar
• Lagrange P. H., Hurtrel B., Ravisse P. La réaction locale granulomateuse après vaccination par le BCG chez la souris. 1.-Description. Ann. l'Inst. Pasteur. Immunol. 1978; 129C: 529–546
   Google Scholar
• Lagrange P. H., Mackaness G. B. A stable form of delayed-type hypersensitivity. J. Exp. Med. 1974; 141(1)82–96
   Google Scholar
• Lagrange P. H., Mackness G. B., Miller T. E. Potentiation of T-cell-mediated immunity by selective suppression of antibody formation with cyclophosphamide. J. Exp. Med. 1974; 139: 1529–1539
   PubMed Web of Science ®Google Scholar
• Launois P., Maillard I., Pingel S., Swihart K. G., Xenarios I., Acha-Orbea H., Diggelmann H., Locksley R. M., Macdonald H. R., Louis J. A. IL-4 rapidly produced by V beta 4 V alpha 8 CD4+T cells instructs Th2 development and susceptibility to Leishmania major in BALB/c mice. Immunity. 1997; 6: 541–549
   PubMed Web of Science ®Google Scholar
• Locksley R. M., Heinzel F. P., Sadick M. D., Holaday B. J., Gardner K. D., Jr. Murine cutaneous leishmaniasis: susceptibility correlates with differential expansion of helper T-cell subsets. Ann. l'Inst. Pasteur. Immunol. 1987; 138: 744–749
   PubMedGoogle Scholar
• Mayrink W., Williams P., da Costa C. A., Magalhaes P. A., Melo M. N., Dias M., Oliveira Lima A., Michalick M. S., Ferreira Carvalho E., Barros G. C. An experimental vaccine against American dermal leishmaniasis: experience in the State of Espirito Santo, Brazil. Ann. Trop. Med. Parasitol. 1985; 79: 259–269
   PubMed Web of Science ®Google Scholar
• McConville M. J., Ralton J. E. Developmentally regulated changes in the cell surface architecture of Leishmania parasites. Behring Inst. Mitt. 1997; 99: 34–43
   Google Scholar
• Mendonça M. G., Brito M. E. F., Rodrigues E. H. G., Bandeira V., Jardim M. L., Abath F. G. C. Persistence of Leishmania parasites in scars after clinical cure of American cutaneous leishmaniasis: is there a sterile cure?. J. Infect. Dis 2004; 198: 1018–1023
   Google Scholar
• Milon G., Marchal G. Increased infiltration by monocytes in delayed type hypersensitivity site following cyclophosphamide treatment. Immunology 1978; 35: 989–995
   PubMedGoogle Scholar
• Modabber F. Vaccines against leishmaniasis. Ann. Trop. Med. Parasitol 1995; 89: 83–88
   PubMed Web of Science ®Google Scholar
• Molano I., Alonso M. G., Miron C., Redondo E., Requena J. M., Soto M., Nieto C. G., Alonso C. A. Leishmania infantum multi-component antigenic protein mixed with live BCG confers protection to dogs experimentally infected with L. infantum. Vet. Immunol. Immunopathol. 2003; 20:92(1–2)1–13
   Google Scholar
• Mougneau E., Altare F., Wakil A. E., Zheng S., Coppola T., Wang Z. E., Waldmann R., Locksley R. M., Glaichenhaus N. Expression cloning of a protective Leishmania antigen. Science 1995; 268: 563–566
   PubMed Web of Science ®Google Scholar
• Nicolle C. H. Culture du parasite du Bouton d'Orient. Compte Rendu Hebdomadaire des Séances de l'Académie des Sciences, Paris 1908; 146: 842–843
   Google Scholar
• Oliveira C. C. G., Lacerda H. G., Maruns D. R. M., Barbosa J. D. A., Monteiro G. R., Queiroz J. W., Sousa J. M. A., Ximenes M. F. F. M., Jeronimo S. M. Changing epidemiology of American cutaneous leishmaniasis (ACL) in Brazil: a disease of the urban-rural interface. Acta Trop. 2004; 90: 155–162
   PubMedGoogle Scholar
• Pereira N. M., Timm S. L., Gonçalves da Costa S. C., Rebello M. A., De Souza W. Trypanosoma cruzi: isolation and characterization of membrane and flagellar fractions. Exp. Parasitol 1978; 46: 225–234
   PubMedGoogle Scholar
• Piccinni E., Albergoni V. ATPase activity in isolated flagella from. Euglena gracilis. J. Protozool 1973; 20: 456–458
   Google Scholar
• Piras M. M., de Rodriguez O. O., Piras R. Trypanosoma cruzi: antigenic composition of axonemes and flagellar membranes of epimastigotes cultured in vitro. Exp. Parasitol 1981; 51: 59–73
   PubMedGoogle Scholar
• Requena J. M., Alonso C., Soto M. Evolutionarily conserved proteins as prominent immunogens during Leishmania infections. Parasitol. Today 2000; 16(6)246–250
   PubMedGoogle Scholar
• Sadowski P. D., Steiner J. W. Isolation of two distinct classes of polysomes from a nuclear fraction of rat liver. J. Cell. Biol 1968; 37: 147–162
   PubMedGoogle Scholar
• Salem M. L., Kadima A. N., EL-Naggar S. A., Rubinstein M. P., Chen Y., Gillanders W. E., Cole D. J. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. J. Immunother 2007; 30(1)40–53
   Web of Science ®Google Scholar
• Schottelius J., Gonçalves da Costa S. G. Studies on the relationship between lectin binding carbohydrates and different strains of Leishmania from the New World. Mem. Inst. Oswaldo Cruz 1982; 77: 19–27
   PubMedGoogle Scholar
• Schubach A., Cuzzi-Maya T., Oliveira A. V., Sartori A., Oliveira-Neto M. P., Mattos M. S., Araújo M. L., Souza W. J. S., Haddad F., Perez M. A., Pacheco R. S., Momen H., Coutinho S. G., Marzochi M. C. A., Belizia K., Marzochi F., Gonçalves da Costa S. C. Leishmanial antigens in the diagnosis of active lesions and ancient scars of American tegumentary leishmaniasis patients. Mem. Inst. Oswaldo Cruz 2001; 96: 987–996
   PubMed Web of Science ®Google Scholar
• Schubach A., Marzochi M. C. A., Cuzzi-Maya T., Oliveira A. V., Araújo M. L., Oliveira A. L. C., Pacheco R. S., Momen H., Conceição-Silva F., Coutinho S. G., Marzochi K. B. F. Cutaneous scars in American tegumentary leishmaniasis patients: a site of Leishmania (Viannia) braziliensis persistence and viability eleven years after antimonial therapy and clinical cure. Am. J. Trop. Med. Hyg 1998; 58: 824–827
   PubMedGoogle Scholar
• Schuck S., Honso M., Ekross K., Shevchenko A., Simons K. Resistance of cell membranes to different detergents. Proc. Natl. Acad. Sci. USA 2003; 100: 5795–5800
   PubMed Web of Science ®Google Scholar
• Shehadeh N., Calcinaro F., Bradley B. J., Bruchlim I., Vardi P., Lafferty K. J. Effect of adjuvant therapy on development of diabetes in mouse and man. Lancet 1994; 343: 706–707
   PubMed Web of Science ®Google Scholar
• Silva J. S., Rossi M. A. Intensification of acute Trypanosoma cruzi myocarditis in Balb/mice pretreated with low doses of cyclophosphamide or gamma irradiation. Int. J. Exp. Pathol 1990; 71: 33–39
   Google Scholar
• Skeiky Y. A., Kennedy M., Kaufman D., Borges M. M., Guderian J. A., Scholler J. K., Ovendale P. J., Picha K. S., Morrissey P. J., Grabstein K. H., Campos-Neto A., Reed S. G. LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile. J. Immunol. 1998; 161: 6171–6179
   PubMed Web of Science ®Google Scholar
• Smrkovski L. L., Larson C. L. Effect of treatment with BCG on the course of visceral leishmaniasis in BALB/c mice. Infect. Immun. 1977; 18: 561–562
   PubMedGoogle Scholar
• Taswell C. Limiting dilution assays for the determination of immunocompetent cell frequencies, I. Data analysis. J. Immunol 1981; 126: 1614–1622
   PubMed Web of Science ®Google Scholar
• Titus R. G., Gueiros-Filho F. J., De Freitas L. A., Beverley S. M. Development of a safe live Leishmania vaccine line by gene replacement. Proc. Natl. Acad. Sci. USA 1995; 92: 10267–10271
   PubMed Web of Science ®Google Scholar
• Titus R. G., Marchand M., Boon T., Louis J. A. A limiting dilution assay for quantifying Leishmania major in tissues of infected mice. Parasite Immunol 1985; 7: 545–555
   PubMed Web of Science ®Google Scholar
• Turk J. L., Parker D., Poulter L. W. Functional aspects of the selective depletion of lymphoid tissue by cyclophosphamide. Immunology 1972; 23: 493
   PubMed Web of Science ®Google Scholar
• Wrightsman R. A., Miller M. J., Saborio J. L., Manning J. E. Pure paraflagellar rod protein protects mice against Trypanosoma cruzi infection. Infect. Immun. 1995; 63: 122–125
   Google Scholar